MedTrace Logo

Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis

NCT05043194 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-09-20

No results posted yet for this study

Summary

This study aims to confirm whether the preventive use of ursodeoxycholic acid on the 5th day after birth in preterm infants who started parenteral nutrition therapy can reduce the occurrence of enteral nutrition-related cholestasis in preterm infants. This study examined the safety and efficacy of ursodeoxycholic acid (UDCA) in preventing Cholestasis Associated with Total Parenteral Nutrition in preterm infants.

Conditions

  • Cholestasis of Parenteral Nutrition

Interventions

DRUG

Ursodeoxycholic Acid 250 Mg Oral Capsule

prevention

Sponsors & Collaborators

  • Wei Liu

    lead OTHER

Principal Investigators

  • liwen chang · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Day
Max Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-09-30
Completion
2022-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043194 on ClinicalTrials.gov